Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Palmoplantar Pustulosis

Next Previous
Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Palmoplantar Pustulosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Guselkumab (Primary)
  • Indications Palmoplantar pustulosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen Pharmaceutical KK

Most Recent Events

  • 01 Dec 2021 Results assessing efficacy and safety of guselkumab through W84, and to explore factors associated with the sustainability of its efficacy in Japanese PPP patients published in the Journal of Dermatology
  • 12 Aug 2021 Results of pool analysis from phase 2 (NCT01845987) and phase 3 (NCT02641730) of guselkumab, assessing the longitudinal profile of PPPASI score improvement by guselkumab treatment and clinical implications of guselkumab dose, baseline disease severity and smoking on the treatment effect, by using pharmacokinetic and pharmacodynamic modeling, published in the Journal of Clinical Pharmacology.
  • 03 Jul 2019 Results published in the JAMA Dermatology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top